Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.
Company Info
SIC2836
Composite FIGI—
CIK0001674416
IPOOct 19, 2016
Sectorbiological products, (no diagnostic substances)
The chart shows the growth of an initial investment of $10,000 in CRISPR Therapeutics AG, comparing it to the performance of the S&P 500 index. All prices have been adjusted for splits and dividends.
Returns By Period
CRISPR Therapeutics AG (CRSP) has returned -6.09% so far this year and 60.36% over the past 12 months. Looking at the last ten years, CRSP has achieved an annualized return of 12.68%, outperforming the Benchmark (SPY), which averaged 12.23% per year.
CRSP
1M-10.94%
6M-29.58%
YTD-6.09%
1Y60.36%
5Y-15.51%
10Y12.68%
Benchmark (SPY)
1M-1.58%
6M-2.48%
YTD-4.36%
1Y34.06%
5Y9.80%
10Y12.23%
Monthly Returns
The table below presents the monthly returns of CRISPR Therapeutics AG (CRSP) with color gradation from worst to best to easily spot seasonal factors.
Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
2026
-5.24%
21.49%
-18.04%
3.38%
2025
4.47%
9.28%
-24.65%
13.77%
-6.15%
32.39%
16.26%
-4.55%
27.10%
-1.17%
-15.15%
0.27%
2024
1.79%
32.65%
-19.20%
-22.24%
1.09%
-1.48%
6.05%
-16.85%
-0.82%
-1.30%
8.97%
-23.00%
2023
23.87%
-4.36%
-8.09%
8.06%
31.63%
-12.36%
2.07%
-12.19%
-10.40%
-13.97%
53.58%
-5.47%
2022
-16.74%
-5.85%
3.91%
-21.92%
17.08%
4.65%
22.73%
-12.04%
2.08%
-20.72%
1.82%
-24.97%
2021
4.99%
-26.29%
-4.62%
4.73%
-10.48%
35.54%
-24.93%
2.30%
-10.56%
-18.27%
-12.68%
-5.83%
2020
-14.40%
5.80%
-21.46%
17.06%
32.74%
13.24%
13.96%
8.00%
-9.08%
9.40%
37.06%
17.80%
2019
16.49%
9.03%
-0.31%
10.87%
-11.47%
32.71%
6.09%
-10.15%
-10.27%
22.67%
39.59%
-16.02%
2018
63.67%
23.78%
-5.56%
3.10%
46.71%
-17.03%
-17.69%
18.71%
-24.19%
-26.36%
16.61%
-28.49%
2017
-15.48%
35.60%
-7.36%
-22.64%
-19.88%
16.42%
9.52%
17.03%
-12.36%
6.69%
-2.11%
23.25%
2016
21.67%
16.81%
-6.51%
Performance Indicators
The charts below present risk-adjusted performance metrics for CRISPR Therapeutics AG (CRSP) and compare them to a Benchmark (SPY). These indicators evaluate an investment's returns against its associated risks.
Sharpe ratio
Sortino ratio
Omega ratio
Calmar ratio
Martin ratio
sharpe ratio
The Sharpe ratio helps investors understand how much return they're getting for the level of risk taken. A higher Sharpe ratio indicates better risk-adjusted performance, meaning more reward for each unit of risk.
These values reflect how efficiently the investment has delivered returns relative to its volatility over different time periods. All figures are annualized and based on daily total returns.
The chart below shows the rolling Sharpe ratio of CRSP compared to the benchmark. This view highlights how the investment's risk-adjusted performance has changed over time.
Volatility Chart
The current CRISPR Therapeutics AG volatility is 3.73%, representing the standart deviation of percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. It shows the maximum percentage drop from a peak to a trough over a specified period, indicating the risk of significant losses. Although chart shows positive values, it represents the percentage drop from the peak, so a value of 10% means the portfolio has dropped 10% from its highest point.
Income Statement
The income statement provides a summary of a company's revenues, expenses, and profits over a specific period. It shows how much money the company earned (revenues) and how much it spent (expenses), leading to the net income or profit. This statement is crucial for understanding a company's financial performance and profitability.
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
Liabilities And Equity (USD)
2.27B
2.24B
2.23B
2.24B
2.75B
1.83B
1.07B
489.02M
271.35M
344.96M
Equity Attributable To Parent (USD)
1.92B
1.93B
1.88B
1.88B
2.40B
1.66B
939.43M
392.20M
187.83M
232.85M
Equity Attributable To Noncontrolling Interest (USD)
Avaí Bio announced a critical milestone in creating a Master Cell Bank of genetically modified cells that overexpress the α-Klotho protein, an anti-aging protein that declines by 50% after age 40. The company is partnering with Austrianova to use Cell-in-a-Box encapsulation technology for its Klothonova anti-aging and Insulinova diabetes programs. This development occurs as the cell and gene therapy market expands rapidly, with the sector forecast to grow from $10.4 billion to over $45 billion by 2035.
Benzinga•Equity-Insider.Com
AI Insight
Company reported strong Phase 1 data for CTX310 showing significant reductions in cardiovascular risk markers (73% ANGPTL3, 55% triglycerides, 49% LDL cholesterol) with a single-dose approach, demonstrating therapeutic potential.
CRISPR Therapeutics stock has declined 9% this year following a $585.2 million convertible notes offering. While the company has an approved gene-editing therapy (Casgevy) and strong financial reserves of $1.8 billion, it remains deeply unprofitable with a net loss of $581.6 million and minimal revenue of $3.5 million. The analyst suggests it may be worth considering as a mid-cap growth stock with potential upside, though not a bargain due to inherent risks.
The Motley Fool•David Jagielski, Cpa
AI Insight
The company has promising technology and an approved therapy (Casgevy) with strong cash reserves ($1.8B), but faces significant challenges including massive net losses ($581.6M), minimal revenue ($3.5M), and dilutive equity offerings. The analyst views it as a speculative mid-cap opportunity with potential upside rather than a clear buy or sell.
CRISPR Therapeutics announced a $350 million convertible debt offering to fund drug development, causing its stock to plunge 12%. While the market reacted negatively due to potential shareholder dilution, analysts maintain a bullish outlook with a $81.21 price target, suggesting the capital raise was likely anticipated and the dip may present a buying opportunity for risk-tolerant investors.
The Motley Fool•James Brumley
AI Insight
Stock fell 12% on announcement of $350M convertible debt offering that could dilute existing shareholders. However, the article notes this decline may be an overreaction, as analysts maintain a bullish consensus price target of $81.21 (50% above current price) and the capital raise was likely anticipated by the market. The company's successful gene therapy approvals and five ongoing clinical trials support long-term potential despite near-term negative sentiment.
The article compares CRISPR Therapeutics and Vertex Pharmaceuticals as gene-editing investment options. While CRISPR has higher upside potential through its pipeline candidates like CTX310, it relies heavily on Casgevy, which faces slow adoption due to complexity and high cost ($2.2M per treatment). Vertex offers a safer alternative with a diversified product portfolio generating consistent revenue and profits, making it better suited for risk-averse investors despite lower upside potential.
The Motley Fool•Prosper Junior Bakiny
AI Insight
High upside potential from promising pipeline candidates (CTX310 for cholesterol treatment) but significant downside risk due to heavy reliance on single approved drug (Casgevy) with slow commercial adoption, consistent losses, and clinical execution risk.
CRISPR Therapeutics has achieved a major milestone with Casgevy, the first CRISPR gene-editing therapy approved for rare blood diseases. The company has several promising pipeline candidates including zugo-cel for cancers and autoimmune diseases, CTX310 for cholesterol management, and SRSD107 as a next-gen anticoagulant. While the biotech's platform shows significant potential to revolutionize treatment standards, success depends on clinical execution. The analyst believes the company is more likely to be acquired than go to zero, making it suitable for volatility-tolerant investors.
The Motley Fool•Prosper Junior Bakiny
AI Insight
The company has achieved a major regulatory milestone with Casgevy's approval as the first CRISPR gene-editing therapy. Multiple promising pipeline candidates with potential to address high unmet medical needs are in development. The analyst expresses confidence that the company is more likely to succeed or be acquired than fail completely, despite acknowledging execution risks and clinical trial uncertainties.
CRISPR Therapeutics stock rose over 12% following Q4 2025 earnings despite posting larger-than-expected net losses and minimal revenue ($0.86M) due to its revenue-sharing partnership with Vertex Pharmaceuticals on CASGEVY. The gene-editing company is in early stages with its flagship sickle cell/beta thalassemia therapy generating $54M in sales, while its pipeline candidate CTX611 for blood clot prevention shows promise. With $1.9B in cash providing 3-4 years of runway, analysts maintain a Hold consensus, though the stock trades near its 200-day moving average with downside risks.
Investing.com•Chris Markoch
AI Insight
Stock gained 12% post-earnings despite weak near-term financials. The company has moved past proof-of-concept with FDA-approved CASGEVY and promising pipeline candidates like CTX611. Strong cash position ($1.9B) provides runway for development. Long-term growth potential outweighs current operational losses, making it suitable for patient investors with multi-year horizons.
CRISPR Therapeutics is highlighted as a promising biotech investment for 2026. The company's CRISPR-based gene-editing treatment Casgevy received FDA approval for blood disorders and has multi-billion-dollar potential. Multiple clinical trial updates and new trial launches are expected throughout 2026, which could serve as catalysts for stock growth.
The Motley Fool•Adria Cimino
AI Insight
The article presents CRISPR Therapeutics as a 'blastoff-ready' biotech stock with proven technology (FDA-approved Casgevy), multi-billion-dollar revenue potential, and multiple clinical catalysts expected in 2026. The author recommends buying the stock and suggests investors will regret not purchasing it.
CRISPR Therapeutics reported strong Q4 2025 results with Casgevy gene therapy generating $116 million in annual revenue and 147 patient initiations, nearly tripling from 2024. The company is advancing its pipeline with in vivo liver editing programs and RNA-based candidates. Shares surged 8.81% on the positive clinical progress and expanding market access.
Benzinga•Vandana Singh
AI Insight
Strong Q4 results with Casgevy revenue of $116M annually, patient initiations nearly tripling YoY to 147, expanding reimbursement coverage (~90% of eligible U.S. patients), and promising pipeline progress across multiple therapeutic areas. Stock up 8.81% reflects market confidence.
CRISPR Therapeutics is positioned as an alternative investment to AI stocks, leveraging gene-editing technology to develop therapies for hard-to-treat diseases including Type 1 diabetes, anticoagulation disorders, and high cholesterol. While the company offers significant upside potential with its pipeline candidates and approved Casgevy medicine, it carries clinical and regulatory risks typical of early-stage biotech companies.
The Motley Fool•Prosper Junior Bakiny
AI Insight
The article highlights CRISPR's promising gene-editing platform, multiple clinical candidates addressing high unmet medical needs (Type 1 diabetes, anticoagulation, cholesterol), and an already-approved medicine (Casgevy). The company is positioned as offering 'massive upside potential' and attractive returns for risk-tolerant investors seeking non-AI exposure.
CRISPR Therapeutics AG, a major holding in Cathie Wood's ARK funds, faces significant headwinds as its momentum score plummeted from 76.81 to 50.97 following a 10% stock decline. The decline was triggered by CEO insider share sales exceeding 90,000 shares and disappointing Q3 revenue of just $890,000, far below the $8.06 million consensus estimate, signaling weak product adoption.
Benzinga•Vishaal Sanjay
AI Insight
Stock declined over 10% due to CEO insider sales of 90,000+ shares and significantly missed Q3 revenue expectations ($890K vs $8.06M consensus), indicating weak product adoption and investor confidence erosion. Momentum score dropped sharply from 76.81 to 50.97.
